MEI Pharma
MEI Pharma is a San Diego, USA-based oncology company focused on the clinical development of novel therapies for cancer.
The firm's pipeline of clinical-stage drug candidates includes Pracinostat, an oral HDAC inhibitor partnered with Helsinn; ME-401, a highly differentiated, oral PI3K delta inhibitor; Voruciclib, an oral, selective CDK inhibitor; and ME-344, a novel mitochondrial inhibitor.
Latest MEI Pharma News & Features
2 March 2023
25 February 2023
Today's issue
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze